Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biomarin Pharmaceuticals
(NQ:
BMRN
)
82.44
-1.36 (-1.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
January 30, 2023
Via
Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
Via
InvestorPlace
Cramer Is Holding This Biotech Stock
January 12, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).
Via
Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
January 11, 2023
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
January 11, 2023
Via
Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
January 11, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
January 10, 2023
Some stocks are hitting new highs.
Via
The Motley Fool
Expert Ratings for Biomarin Pharmaceutical
November 29, 2022
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
October 31, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
October 27, 2022
Investors were expecting better top-line numbers from the company's earnings report.
Via
The Motley Fool
Top Picks For 2023: Catalyst Pharmaceuticals
January 02, 2023
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
December 01, 2022
Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about!
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
October 13, 2022
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Via
Benzinga
One Rejected BioMarin's Hemophilia Gene Therapy Goes Under FDA Review
October 13, 2022
Via
Benzinga
BioMarin Lays Off 4% Of Its Workforce To 'Simplify' The Company
October 07, 2022
Via
Benzinga
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
November 23, 2022
Via
Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
November 23, 2022
And shares of its developer are on a warpath this week.
Via
Investor's Business Daily
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today
November 23, 2022
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe...
Via
Benzinga
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
November 03, 2022
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
10 Analysts Have This to Say About Biomarin Pharmaceutical
October 31, 2022
Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
October 31, 2022
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
Biomarin Pharmaceutical: Q3 Earnings Insights
October 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Biomarin Pharmaceutical Q3 Earnings
October 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial
September 12, 2022
Via
Benzinga
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.